% | $
Quotes you view appear here for quick access.

Arena Pharmaceuticals, Inc. Message Board

  • tiger_josef tiger_josef Mar 24, 2013 6:31 AM Flag

    As posted on MNKD MB Ref: T2 Diabetes.

    Just FYI and to say T2 Diabetics need BELVIQ and they need it NOW, including myself.
    jt1550 • 5 hours ago
    Heart warning on Type 2 diabetes drugs
    FDA announced today that manufacturers of certain drugs approved to treat type 2 (non-insulin-dependent) diabetes have agreed to add the agency's strongest warning—"boxed"—on the risk of heart failure. This cardiovascular condition occurs when the heart does not adequately pump blood.

    Which Drugs Will Receive the Warning?
    The upgraded warning emphasizes that the following medications in the class of antidiabetic drugs (thiazolidinediones) may cause or worsen heart failure in certain patients:

    Avandia (rosiglitazone)
    Actos (pioglitazone)
    Avandaryl (rosiglitazone and glimepride)
    Avandamet (rosiglitazone and metformin)
    Duetact (pioglitazone and glimepride)
    These drugs are used together with diet and exercise to improve blood sugar control in adults with type 2 diabetes. Less

    Sentiment: Strong Buy

    SortNewest  |  Oldest  |  Most Replied Expand all replies
    • Don't let those get to you on this board making accusations of your character bother you Tiger. Longs appreciate your posts, thoughts and ideas that are provoking. Can't let those types bother you and prevent you from adding some worth to this board. As far as the T2D medications, I think we will only benefit from this latest news as many physicians will use Belviq as a double wamy on weight loss and T2D since they will be able to prescribe off label. It's all good. Good Luck to you.

      Sentiment: Strong Buy

    • jcw101245 Mar 24, 2013 8:40 PM Flag

      Tiger - Are you saying that you are currently taking one of the aformentioned drugs and plan on changing to Belviq, which has not been approved by the FDA for type 2 diabetes? You apparently garnered this information on another MB and reposted it here like it is breaking news. It is not! Unless your diabetes physician is DR. HENRY, I seriously doubt that he would presrcibe a medication that may be detrimental to your health. Frankly, you are beginning to sound more like a snake oil salesman than the supposed expert that some of your hacks who respond to your posts think that you are.

      Sentiment: Hold


    • wouldn't blame you for not posting but hope you are appreciated.

    • Nice Post Tiger

      You being a plant??? HAHAHAHA you have helped all true longs all along the way.

      Look forward to the information you find as well as all of your detailed NPV of stock price.

      Sentiment: Buy

    • In my opinion, Belviq got a huge win when theygot the A1c reductions put in the prescribing information. A huge percentage of scripts are written off label. With that info in the label it is fair game to be discussed and considered even before the diabetes trials are done and Belviq goes for that indication. I believe that will also add to the patent life if we gain an indication for diabetes also down the road.

      Sentiment: Strong Buy

    • edimartino Mar 24, 2013 12:31 PM Flag

      Tiger do not let the bullies and mentally challenged run you off this board. I only read less then ten posters so again stay long and prosper. I think in a few years we will be in great shape no matter what the geniuses and bashers tell us.

    • Tiger and Daduke... I agree with you daduke. ARNA and MNKD are my 2 top biotech holdings. Tiger are you in mnkd also? The information you post is appreciated by many. Many thanks for all of your past effort and also for the future if you so chose. In regard to the TZD class. In my personal opinion the CHF risk is well know and a black box will not have a big impact on sales dropping. They have already had sale decimated. The restrictions placed on the Avandia family are much tougher than even the vivus REMS due to more broad heart related concerns. Avandia, Avandamet, Avandaryl sales for all intent and purpose died years ago. As for the other TZD family of products the bladder cancer concerns and August '12 loss of patent protection slashed sale. The generic options for the pioglitazone family are just getting to the point where competition will heat up and drop the price. (first generic gets a opportunity for something like 6 months at an exclusive so the price vs branded doesn't drop that much right away) So we will know if generic pricing stabilizes pio sales but the trend is way down. The real question is the DPP4 class Januvia and the other 3 entrants. They are all doing required post marketing CV safety trials to my knowledge and I believe there are also concerns cropping up with pancreatic issues. Belviq could really have a large opportunity as a blood sugar lowering addition to others in the diabetes controlling cocktail. Most type 2's are on 2-3 Blood sugar lowering meds.

      Sentiment: Strong Buy

      • 1 Reply to trxvolume
      • Thanks for the reply patenright1. Glad you guys are in mnkd too, it's good to know i'm in good company. I have respected your posts over my time on the boards. I hold shares in mnkd, cost avg of 2.83 and $2- 2015 calls. I was very early in mnkd shares (aka. wrong, lol) and have averaged down for a long time.

        Sentiment: Strong Buy

    • Tiger post what you want, its up to you..The t2 diabetes thing was very good, thanks...I would of not known that

    • WOW, Tiger..Belviq s need will be great..Thanks

2.15+0.02(+0.94%)Nov 27 1:00 PMEST